Arcutis Biotherapeutics, Inc. (ARQT) Stock Grade

About Arcutis Biotherapeutics, Inc.'s fundamentals

Arcutis Biotherapeutics is a biotechnology company with a $3.4 billion market capitalization that has demonstrated substantial revenue growth of 91.3% year-over-year, indicating strong commercial traction. However, the company reported a net loss in its latest annual statement with a negative net margin of -4.3%, meaning it is not yet profitable despite its revenue expansion. The company's P/E ratio of 108.4 reflects the market's pricing of a pre-profitability biotech firm, and the company does not pay a dividend. This profile is typical of growth-stage biotechnology companies that prioritize revenue expansion and research investment over near-term profitability.